Insulin Glargine in Critically ill Patients: Once/Day versus Twice/Day Dosing

Abstract

Objective Twice/day dosing of insulin glargine has been used to treat hyperglycemia in clinical practice; however, data supporting its use in the critically ill population are lacking. This study was designed to evaluate the safety and efficacy of twice/day insulin glargine in critically ill patients. Methods A retrospective study was conducted in adult patients admitted to the intensive care units between February 2013 and June 2017 who received insulin glargine twice/day or 40 units or more once/day for 48 hours or longer. Post cardiovascular surgery patients were excluded. Data were collected for up to 14 patient‐days. The efficacy outcomes included the incidence of hyperglycemia (blood glucose [BG] above 180 mg/dl), predose hyperglycemia rate (BG above 180 mg/dl within 4 hrs before the dose), and BG variability (standard deviation). The safety outcome was assessed by the development of hypoglycemia (BG below 70 mg/dl). Results A total of 58 patients (twice/day = 23; once/day = 35) were included in the analysis. Demographics were similar between the groups including history of diabetes mellitus, baseline hemoglobin A1C, and home insulin use. No difference was observed between the twice/day and once/day groups in the mean BG (153 vs 154 mg/dl, p=0.95, respectively), and BG variability (46 vs 44 mg/dl, p=0.29, respectively). Although the overall incidence of hyperglycemia was similar between twice/day and once/day groups (96% vs 97%, p=1.00, respectively), the twice/day group had a significantly lower predose hyperglycemia rate (twice/day 0.27 vs once/day 0.43, p=0.02). Additionally, the twice/day group did not experience an increased incidence of hypoglycemia (twice/day 23% vs once/day 34%, p=0.57) or hypoglycemia without having anything by mouth (twice/day 0% vs once/day 9%, p=0.27). Conclusions This is the first study demonstrating that twice/day insulin glargine reduced the rate of predose hyperglycemia without increasing the risk of hypoglycemia in critically ill patients. A large randomized study is needed to confirm the safety and efficacy of twice/day glargine in the critically ill.

Significant Published Articles in 2020 for Pharmacy Nutrition Support Practice

“…Five papers from the primary literature were collectively identified (receiving 5 or more votes) as most important by the authors. [25][26][27][28][29] Results from the sorting process are depicted in Figure 1.…”

Hypoglycemic Agents and Anesthetic Techniques to Ameliorate Stress Hyperglycemia in Critically Ill Patients: A Systematic Review

“…Fox et al . [ 32 ] conducted a retrospective study supporting the safety and efficacy of twice-daily insulin glargine in stable critically ill patients.…”

Recommendations of the Working Groups from the Spanish Society of Intensive and Critical Care Medicine and Coronary Units (SEMICYUC) for the management of adult critically ill patients in the coronavirus disease (COVID-19)

“…Se recomienda evitar tanto la hipoglicemia como la variabilidad glucémica por su importante repercusión en la morbimortalidad del paciente crítico 77 . La utilización de insulinas lentas cada 12 h, nos pueden ayudar en el manejo de la hiperglicemia de estrés evitando hipoglicemias y disminuir la necesidad de iniciar perfusión de insulina 78 dada la escasez de bombas y el exceso de trabajo del personal sanitario.…”